TX-FLUENCE
1.2.2024 14:31:34 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the successful continuation of its partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization that focuses on molecular farming and medicinal plants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201728532/en/
Fluence and Innexo's partnership tests the effects of eliminating the vegetation phase for cannabis cultivation. (Photo: Business Wire)
Fluence and Innexo’s research partnership is focused on assessing the viability of cultivating cannabis without a standard vegetative phase, a practice generally associated with lower energy use that passes savings directly to growers in Europe and around the globe. Preliminary data from Fluence and Innexo demonstrates the potential of the “no-veg” growing method to help growers save money while improving quality and consistency. The Fluence and Innexo teams intend to collaborate on a full-scale research project to validate these initial results.
“At Innexo, we use our deep knowledge of cannabis cultivars and best propagation practices to help growers create the most efficient cultivation strategies possible,” said Dominique van Gruisen, managing director of Innexo. “We naturally gravitate toward partners like Fluence who can match our expertise and commitment to investing in innovative and impactful cannabis research.”
Most commercial cannabis cultivators use a vegetative phase to ensure proper plant growth to support flower weight and to gain a full and dense canopy. This phase can last anywhere between seven days and four weeks, requiring a significant investment of time, electrical energy and resources. Initial findings from Fluence and Innexo demonstrate the potential of this method to maintain crop quality and yield while creating up to 55% savings on annual electrical costs directly associated with lighting.
When the plants would typically enter the vegetative phase, they were instead transplanted to the flowering room, where they immediately received their maximum light intensity. In this system, cannabis crops reach their final height—between 70 and 120 cm—around 28 days after transplant. Eliminating two weeks of vegetative phase represents up to 252 hours of direct electricity savings per light per crop cycle. Additional savings are realized through lower HVAC costs and generally more efficient cultivation cycles. Initial research indicates that “no-veg” growing is most effective with plant densities between eight and 10 plants per m2. Thus far, research has tested the viability of “no-veg” growing across six cannabis cultivars, 10 different nutrient lines and a wide range of light intensities.
“Proper lighting—which must include a strong combination of advanced fixtures and lighting strategy—plays a critical role in creating a more efficient and profitable methodology for cannabis cultivation,” said Dr. David Hawley, principal scientist at Fluence. “This research demonstrates the value of examining and investing in a research-backed lighting strategy from day one. Our goal is to explore, validate and demonstrate the effectiveness of diverse cultivation strategies to ensure every grower can apply data-driven methodologies to their facilities in collaboration with Fluence.”
Fluence and Innexo’s research uncovered potential savings for growers who pursue growing without a vegetative phase, including an average of both 40% lower electrical costs and up to 40% lower labor costs per crop cycle. Because of the fast-paced growth of the plants, researchers found there was less time for pests and diseases to develop, leading to a healthier end product. In addition, this method could reduce waste by eliminating C-Grade flower, which allows for more crop cycles per year and increases overall predictability for growers.
“At Fluence, we create value for growers throughout the world by investing in research that will expand the horizons of traditional cultivation,” said Sebastian Olschowski, research project manager for EMEA at Fluence. "As plant lighting specialists, we are proud to be part of this project to shape the future of cannabis research and transfer valuable knowledge to our customers and partners.”
Fluence and Innexo’s research collaboration, which began in 2022, has expanded to include collaborations in three of Innexo’s Acceleration Platform for Innovation (API) programs. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation.
For more information on Fluence and its ongoing global research initiatives, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
About Innexo BV
Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit www.innexo.nl.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201728532/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
